查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球药物输送设备市场-2022-2029
市场调查报告书
商品编码
1143392

全球药物输送设备市场-2022-2029

Global Drug Delivery Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

药物输送设备市场规模预计在 2021 年和 2029 年分别达到 780.9 亿美元和 1248.3 亿美元，在我预计的预测期内（2022-2029 年）以 5.6% 的复合年增长率增长。

药物输送装置是用于通过特定给药途径将药物和治疗剂输送到人体和各种系统的专用装置。这些设备可以在医疗程序中使用一次或多次。

市场动态

药物输送设备市场的增长受到多种因素的推动，例如慢性病增加、生物製剂市场增长、技术进步和新产品推出。此外，全球冠状病毒的爆发导致对药品的需求激增，主要是针对传染病。

预计慢性病患病率上升和政府资金增加将推动市场增长。

此类癌症的高发病率增加了研发工作，以开发新的药物输送系统，为患者提供更好的治疗。在癌症治疗药物输送中使用创新技术正在推动市场。对药物自我给药的日益增长的需求，例如在糖尿病等疾病中，正在推动无针给药装置的工业规模。

多年来，药物输送设备经历了许多创新。多年来，药物输送领域出现了许多创新，并且没有迹象表明很快就会放缓。一些改进了现有技术，如胰岛素输送装置和吸入器，而另一些则解锁了通过各种方式输送药物的新方法。该领域最好的创新者是美敦力和 Tandem Diabet Care 等大公司。此外，崭露头角的公司开始传播，对治疗剂新给药方法的研究仍在继续。

例如，总部位于辛辛那提的 Enable 2019 与赛诺菲合作，利用赛诺菲提供的多个分子开发计划建立了一个长期的製造和供应结构。 Enable Injection 正在开发一种带有 enFuse 的皮下给药平台，该平台可用作身体贴片。 enFuse 使患者能够在医院外皮下输送大剂量的治疗药物。这种体内药物输送平台具有与标准注射器和小瓶容器格式兼容的独立药物输送系统。

药物输送设备变得越来越复杂，以简化患者和医疗保健专业人员的药物输送。当今的许多设备都具有旨在促进自我管理和鼓励患者遵守新方案的特殊功能。可穿戴设备通过促进积极的生活方式使我们更加方便。一些设备还提供连接功能以支持数字健康监测。

製药行业的严格监管和低质量预计将阻碍市场增长。

当公司没有意识到每个行业的质量和监管要求略有不同，并且配方产品的成分也受到略有不同的监管时，通常会出现最大的挑战。

近年来，注射给药领域的产品召回事件屡见不鲜。召回可能是自愿发生的，也可能是在监管干预之后发生的。在开发过程中必须识别和解决可用性问题。可注射保留样品测试过程中可见异物的存在可能导致严重的健康危害，例如身体功能的永久性损害、血管损伤或阻塞、局部炎症、静脉炎、过敏反应、栓塞和感染。玻璃、硅和不銹钢等无机物质的污染以及小瓶填充不完整也会导致注射剂的召回。

如果产品被召回，在召回和更换缺陷产品的过程中，企业和製造商可能会因更换或修復缺陷产品而遭受巨大损失。这些巨额亏损会影响一家公司的收入和市场份额，进而影响整个市场。关键挑战不是技术本身，而是药品和医疗设备这两个不同领域的整合。

行业分析

针对全球药物输送市场，我们根据波特五力、监管分析、供应链分析、定价分析、未满足需求等多种行业因素对市场进行深入分析。

COVID-19 影响分析

在 COVID-19 大流行期间，大多数製药公司和政府都在努力为 COVID-19 患者提供高效的医疗服务，预计药物输送将在这方面发挥关键作用。我来了。在这个项目中，我们正在开发含有免疫增强剂和靶蛋白的仿生纳米颗粒，并致力于鼻内免疫的原理。此外，COVID-19 已将多种产品（如注射给药和雾化器）推向了前台市场。

由于气雾剂疗法会产生不被患者吸入并在呼气时从设备中释放出来的逸散性排放物，因此一些国际专业机构建议通过吸入器，尤其是雾化器进行药物输送。由于医院将资源集中在治疗 COVID-19 患者上，许多选择性医疗程序被推迟或取消，其他产品的使用量有所下降。大流行为药物输送设备的开发和营销开闢了新途径。 COVID-19 可能会给药物输送设备行业带来重大变化。这可能涉及转向全新的药物输送设备製造系统，迫使许多公司采用新技术。

细分分析

注射给药领域有望占据全球给药器械市场最大份额

根据研究报告，全球市场分为管理途径、应用程序和最终用户。

根据给药途径，市场细分为口服给药、注射给药、眼给药、肺给药、鼻给药、经粘膜给药、植入给药和被动植入给药。按用途分为传染病、癌症、自身免疫性疾病、中枢神经系统疾病、呼吸系统疾病和糖尿病。根据最终用户，它分为医院、门诊手术、家庭护理环境、诊断中心等。

由于技术进步和对生物製剂的需求增加，预计注射给药领域将增长。随着慢性疾病负担的增加、益处和便利性的增加导致对自行注射器的需求增加，而生物製剂市场的增长导致对注射器的需求增加，预计可注射给药装置将迅速增长。自动注射器、笔式註射器和无针注射器等自我注射设备的推出，使得注射给药 (IDD) 变得相对容易，让患者无需医疗专业人员的帮助即可在家中给药。现在您可以.

自动注射器是一种注射器或可穿戴设备，患者可以使用它在家中自行给药。自动注射器让慢性病患者能够控制自己的治疗计划和治疗环境，使他们能够过上更加独立和自由的社会、家庭和职业生活。

许多公司生产自动注射器。例如，2021 年 4 月 13 日，罗氏 (Roche) 的自註射 Xolair (omalizumab) 预充式註射器的生物製品许可申请补充材料获得 FDA 批准，用于所有美国批准的适应症。 Xolair 是第一个也是唯一一个被 FDA 批准用于治疗中度至重度持续性过敏性哮喘、慢性特发性荨麻疹 (CIU) 和鼻息肉的生物製剂。

注射笔是用于通过皮肤给药的装置。笔式註射器的目的是使注射药物更易于使用和使用。注射笔是为需要长期、连续服用激素或药物以控製糖尿病等疾病的患者而设计的。有一次性和可重复使用的笔式註射器。该领域的市场细分日益发展，预计将刺激市场增长。

自动注射器是一种设计用于给药特定剂量药物的设备。大多数自动注射器是一次性使用的弹簧式註射器。自动注射器被简单地设计用于由患者自行给药或由未经培训的人员给药。注射部位取决于药物，但通常是大腿或臀部。

预计可穿戴式註射器在预测期内将呈现最高的增长率。这些可穿戴注射器是一种输送系统，可以佩戴在身体上，以在较长时间内通过皮下输送更大剂量的药物（大于 2mL）。可穿戴注射器用于大容量药物、高粘度药物製剂（如单克隆抗体）和长期、定时的药物注射方案。当使用可穿戴注射器而不是让患者进入医疗机构进行注射临床协助时，体上註射器最有用。

区域分析

北美在全球药物输送设备市场占有最大份额

根据调查结果，全球市场可分为 5 个区域：北美、南美、欧洲、中东和非洲、亚太地区和世界其他地区。

预计北美药物输送设备市场在预测期内将以最高的复合年增长率增长。在北美，美国的份额最大。心脏病是导致死亡的主要原因，给人们、社区、医疗保健提供者和系统带来巨大负担。该地区癌症发病率的上升也推动了该地区的市场增长。根据美国国家癌症研究所的数据，2019 年美国估计将有 1,735,350 例新诊断的癌症病例。因此，这些癌症患者通过注射器给予化疗药物。

预计在美国等国家/地区增加产品批准也将有助于市场增长。 2019 年 3 月，Aptar Pharma 获得了美国 FDA 对鼻给药装置的批准。因此，美国慢性病患病率的增加以及与註射剂相关的新技术的采用可能有助于推动整个市场的增长。

新兴经济体和有利的监管程序是为主要欧洲市场参与者提供重要机会的一些关键因素。新兴经济体和有利的监管程序这是为该地区主要市场参与者提供重要机会的关键因素之一。

诸如癌症和糖尿病等慢性疾病的增加、对自动注射器（尤其是笔式註射器）的需求增加、技术进步、患者依从性以及德国主要製造商的存在等因素正在推动该市场在德国的增长。德国：我们支持增长。德国是所有主要製药和生物技术公司的所在地。这些公司一直在努力推出新产品以增加其市场占有率。

由于该地区的经济高速增长，预计亚太地区将在预测期内呈现最快的增长率。日本、中国和印度等国家的高患者人数也导致各种最终用户采用药物输送设备。该地区的增长主要是由于医疗机构中药物输送系统的高利用率、大部分人口的潜在报销、慢性病（糖尿病和癌症）的增加、老年人口的增长以及对药物代谢的日益了解。这部分是由于人们越来越倾向于个性化和定制的癌症治疗。

在日本，越来越多地使用各种类型的药物输送装置来输送特定类型的药物。 2019年12月，YpsoMate自动注射器进入日本市场，用于特立骨药物的精准输送。推动中国给药装置市场增长的主要因素是慢性病益处负担的增加和便利性，导致对自动注射器的需求增加，从而导致对给药装置的需求增加。

竞争格局

给药设备市场竞争激烈，由几家主要参与者和新进入者组成。为市场增长做出贡献的主要参与者包括Baxter International、Acromed AG、Medtronic、Becton、Dickinson and Company、F. Hoffmann-La Roche Ltd、Novartis AG、3M、Sanofi、Merck &Co., Inc、Pfizer Inc、Bayer AG、GlaxoSmithKline plc、Novosanis等。

主要参与者正在采取多种增长策略，例如产品发布、收购和合作伙伴关係，这有助于全球药物输送市场的增长。例如：

  • 2022 年 5 月，为生物技术和製药业提供药物输送系统和医疗保健解决方案的公司 Gerresheimer AG 宣布投资总部位于美国的 Portal Instruments，该公司开发了下一代无针药物输送技术。两家公司之间的合作将改变注射药物管理，并有助于扩大 Gerresheimer 的创新药物输送技术平台。
  • 例如，2019 年，Novartis和 Shionogi（日本）在德国、英国和荷兰等欧洲主要国家以及其他一些国家商业化了 Rizmoic (Naldemedine)，这是一种用于治疗阿片类药物引起的便秘的新疗法。对于欧洲市场，我们签订了具有优先购买权的合同。
  • 2019 年 12 月，3M 签署了一项协议，以约 6.5 亿美元的价格将其药物输送业务出售给 Altaris Capital Partners, LLC 的关联公司。

值得关注的主要公司

Pfizer Inc.：

概述Pfizer日本公司是一家活跃于生物技术领域的美国跨国製药公司。成立于 1849 年，总部位于纽约市曼哈顿。它是心脏病学、肿瘤学、神经学和免疫学的各种疫苗和药物的製造商。

产品组合

Nekject 预填充注射器。 Neject 是一种预填充一体式註射器，具有多种技术，例如耐热和防潮。专为高效和简单的药物输送而开发。

重大进展。 2022 年 1 月，Pfizer宣布与 Acuitas Therapeutics 达成开发和选择协议，Acuitas Therapeutics 是一家开发脂质纳米颗粒递送系统和基于 m-RNA 的疗法的公司。

全球药物输送设备市场报告提供大约 45 多个市场数据表、40 多个图表和 180 页内容。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
  • 驱动程序
    • 慢性病增加
    • 技术进步的增加
  • 约束因素
    • 质量和严格的监管
  • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 监管分析
  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 注射给药
    • 自註射装置
    • 注射笔
      • 自动注射器
      • 无针注射器
      • 穿戴式註射器
    • 其他
  • 鼻腔给药
    • 粘膜雾化装置
    • 雾化器
    • 鼻窦植入物
    • 喷鼻剂
    • 鼻腔冲洗器
    • 吸入器
    • 其他
  • 口服给药
    • 微针胶囊
    • 口服片剂
    • 其他
  • 局部给药
    • 透皮贴剂配方
    • 其他
  • 植入给药
    • 主动植入给药
    • 被动给药
  • 肺内给药
    • 雾化器
      • 喷射雾化器
      • 超声波雾化器
      • 软雾雾化器
    • 固定剂量吸入器
    • 干粉吸入器
    • 其他
  • 眼科给药
    • 药用隐形眼镜
    • 眼科插入物
    • 其他
  • 其他给药系统
    • 重建交付系统
    • 输液系统
    • 注入器
    • 室友
    • 无针系统
    • 其他

第 8 章. 按应用程序

  • 癌症
  • 感染
  • 呼吸系统疾病
  • 心血管疾病
  • 中枢神经系统疾病
  • 自身免疫性疾病
  • 糖尿病
  • 其他

第 9 章，最终用户

  • 医院
  • 诊断中心
  • 门诊手术中心
  • 居家护理
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • Pfizer Inc.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Johnson & Johnson
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Becton, Dickinson and Company
  • Sanofi
  • Boehringer Ingelheim
  • Merck & Co., Inc.
  • Boston Scientific Corporation
  • Teva Pharmaceuticals Industries Ltd
  • AbbVie Inc.

第 13 章全球药物输送设备市场-DataM

简介目录
Product Code: DMMD1826

Market Overview

Drug Delivery Devices Market size was valued US$ 78.09 billion in 2021 and is estimated to reach US$ 124.83 billion by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Drug delivery devices are specialized equipment used for the delivery of a drug or therapeutic agent through a specific route of administration into the human body and various systems. These devices can be used once or multiple times for medical treatments.

Market Dynamics

The drug delivery devices market growth is driven by several factors including, the rising prevalence of chronic diseases, growth in the biologics market, technological advancements, and new product launches. Also, due to the outbreak of coronavirus worldwide, there is a sudden increase in the demand for pharmaceutical drugs largely for infectious applications.

Increasing prevalence of chronic diseases and rising government funds are expected to drive the market growth.

Due to this high prevalence of cancer, increasing efforts are being made in R&D for the development of novel drug delivery systems for providing better treatment to patients. The use of innovative technologies in drug deliveries for cancer treatment is driving the market. The increasing need for self-administration of drugs as in the case of diseases such as diabetes has enhanced the size of the needle-free drug delivery devices industry.

The drug delivery device has seen plenty of innovation over the years. The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.

For instance, Cincinnati-based Enable 2019 partnered with Sanofi to develop long-term manufacturing and supply arrangements using multiple molecule development programs provided by the company. Enable Injections is developing a subcutaneous drug delivery platform with the enFuse, which works as an on-body patch. enFuse enables patient-administered subcutaneous delivery of high-volume therapeutics outside of the hospital. The on-body drug delivery platform has a self-contained drug transfer system that is compatible with standard syringes and vial container formats.

To simplify drug delivery for patients and practitioners, drug-delivery devices are becoming more complex. Many of today's devices include special features designed to ease self-dosing and encourage patient adherence to novel regimens. Wearable devices are further easing use by promoting active lifestyles. And some devices are offering connectivity to support digital health monitoring.

Stringent regulations in pharma and poor quality are expected to hamper the market growth.

The quality and regulatory requirements in each industry are slightly different, and often the biggest challenges emerge when companies aren't aware that the constituent products of a combination product are also governed slightly differently.

In recent years, there has been numerous product recalls in the injectable drug delivery segment. Recalls can be voluntary or can result after the intervention of regulatory authorities. Usability issues must be identified and addressed during the development process. The presence of visible foreign matter during the testing of retention samples in injectable can cause severe health consequences such as permanent impairment of a body function, damage and/or obstruction of blood vessels, local inflammation, phlebitis, allergic response, and/or embolization in the body and infection. Other reasons due to which injectable face recalls are contamination from inorganic materials such as glass, silicone, and stainless steel, and also due to incomplete filling of vials.

If a product is recalled, the process of retrieving and replacing the defective product may cause a company or a manufacturer to incur huge losses associated with the replacement and fixing of faulty products. These huge losses will affect the revenue and the share of the company in the market, which in turn will impact the overall market. The key challenges are less about the technology itself and more about the integration of two distinct worlds pharma and medical device.

Industry Analysis

The global drug delivery devices market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis and unmet needs.

COVID-19 Impact Analysis

At the outbreak of the COVID-19 pandemic, most pharmaceutical companies and governments are working toward offering efficient medical treatment to the COVID-19 patients, and drug delivery devices are expected to play a vital role in this context. The project is being worked toward developing principles for nasal immunization, developing a biomimetic nanoparticle provided with both immune enhancers and a targeting protein. In addition, COVID-19 has put the market in front of mind, with unparalleled demand for some products like Injectable drug delivery and nebulizer.

Considering that aerosol therapy generates fugitive emissions that are not inhaled by the patient and are released from the device during expiration, several international professional bodies have provided recommendations for drug delivery via inhalers and in particular, nebulizers. Because of the dramatic drop in elective medical procedures, many of which are being postponed or cancelled so that hospitals can focus resources on treating COVID-19 patients results in a drop in the use of other products. The pandemic is encouraging new avenues for drug delivery device development and marketing. COVID-19 has the potential to prompt a sea change in the drug delivery device industry. This may involve a shift towards entirely new drug delivery device manufacturing systems, forcing many companies to adopt new technology.

Segment Analysis

Injectable drug delivery segment is expected to hold the largest market share in global drug delivery devices market

According to the research report the global market is classified into route of administration, application, and end user.

Based on the route of administration, the market is subdivided into oral drug delivery, injectable drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, implantable drug delivery, and passive implantable drug delivery. based on application it is further divided into infectious diseases, cancer, autoimmune diseases, central nervous system disorders, respiratory diseases, and diabetes. based on end-user segment into hospitals, ambulatory surgery centers, home care settings, diagnostic centers, and others.

The injectable drug delivery segment is expected to grow with the increasing technological advancements and demand for biologics. The injectable drug delivery devices are projected to grow fastly due to the growing burden of chronic diseases, benefits, and convenience, which will lead to increased demand for self-injectors and growth in the biologics market, which will lead to increased demand for injectors. With the introduction of self-injection devices such as auto-injectors, pen-injectors, and needle-free injectors, the use of injectable drug delivery (IDD) has become relatively simple, allowing patients to administer drugs at home without the assistance of a medical professional.

Self-Injection devices are injections or wearable devices that a patient can use at home to administer medication to themselves. Self-injection devices give patients with chronic diseases control over their treatment schedule and treatment setting, allowing them more independence and freedom in their social, domestic, and professional lives.

Many companies are manufacturing self-injection devices. For instance, on April 13th, 2021, the FDA approved Roche company's supplemental Biologics License Application for Xolair(omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the first and only FDA-approved biologic for treating moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU), and nasal polyps.

An injector pen is a device used to administer medication through the skin. Injector pens are intended to make injectable medication more accessible and convenient to use. Pen injectors were created for patients who require a continuous long-term dosage of hormones and medications to manage conditions such as diabetes. They are available in both disposable and reusable forms. The increasing advancements are expected to fuel the market growth of this segment.

An autoinjector is a device designed to deliver a specific drug dose. The majority of autoinjectors are single-use, disposable spring-loaded syringes. Autoinjectors are designed to be simple and intended for self-administration by patients or administration by untrained personnel. The injection site varies depending on the drug, but it is usually in the thigh or buttocks.

Wearable injectors are expected to show at highest growth rate during the forecast period. These wearable injectors are delivery systems that attach to the body and allow for administering larger volumes (more than 2 mL) of drug subcutaneously over an extended period. Wearable injectors are used for high-volume medications, pharmaceutical formulations with high viscosities (e.g., monoclonal antibodies), and regimens requiring timed medication injection over a long period. On-body injectors are most useful when wearable injectors are used as an alternative to admitting the patient to a medical facility for clinical support of an injection.

Geographical Analysis

North America region holds the largest market share in the global drug delivery devices market

As per the research study, the global market is divided into majorly five regions such as North America, South America, Europe, the Middle East, Africa, Asia Pacific, and the Rest of the world.

The drug delivery devices market in North America is estimated to grow at a highest CAGR during the forecast period. The United States owns the largest share of the market in the North American region. Heart disease is a leading cause of death that creates an enormous burden on people, communities, and healthcare providers and systems. The rising prevalence of cancer in the region is also driving the growth of the market in the region. According to the National Cancer Institute, 2019, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore, chemotherapy drugs are being delivered to these cancer patients through injectable devices.

In addition, growing product approval in countries such as the U.S. is also expected to contribute to market growth. In March 2019, Aptar Pharma received U.S. FDA approval for nasal drug delivery devices. Hence, the increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.

Developed economies and favorable regulatory procedures are some of the principal factors providing huge opportunities for the major market players in the Europe. Developed economies and favorable regulatory procedures are some of the principal factors providing huge opportunities for the major market players in the region.

Factors such as the increasing prevalence of chronic diseases such as cancer and diabetes, increased demand for self-injection devices particularly pen injectors, technological advancements, patient compliance, and the presence of key market players in Germany are driving the growth of this market in the country. Germany has the presence of all the major pharmaceuticals and biotechnology companies. The companies are constantly taking initiatives to introduce new products in order to grow their presence in the market.

The Asia Pacific is expected to experience the fastest growth rate during the forecast period owing to high economic growth in the region. Moreover, a large patient pool in countries like Japan, China, and India is also leading to the adoption of drug delivery devices by various end-users. The growth in the region is mainly attributed to higher usage of drug delivery systems in healthcare facilities, availability of reimbursement for the majority of the population, increasing prevalence of chronic diseases (diabetes and cancer), growing geriatric population, increased understanding of drug metabolism and increased preference for individual and customized therapy, especially for cancer.

In Japan, different types of drug delivery devices are coming into use for delivering specific types of drugs. In December 2019, YpsoMate autoinjector entered the Japanese market for accurate delivery of Teribone drug. The major factors attributing to the growth of the Chinese drug delivery devices market are the growing burden of chronic diseases benefits, and convenience, leading to increased demand for self-injectors leading to increased demand for drug delivery devices.

Competitive Landscape

The drug delivery devices market is highly competitive and consists of several major players and the emergence of new players in the market. Some of the key players which are contributing to the growth of the market are Baxter International, Acromed AG, Medtronic, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Novartis AG, 3M, Sanofi, Merck & Co., Inc, Pfizer Inc, Bayer AG, GlaxoSmithKline plc, Novosanis, among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the global market for drug delivery devices. For instance,

  • In May 2022, Gerresheimer AG, company providing drug delivery system and healthcare solutions for biotech, pharmaceuticals announced its investment in Portal Instruments, U.S. based company that developed next generation needle free drug delivery technology. Their partnership will transform the injectable medicine's administration and help Gerresheimer expand its innovative drug delivery technologies platform.
  • For instance, in 2019, Novartis signed an agreement with Shionogi (Japan) to commercialize a new treatment, Rizmoic (Naldemedine) for Opiod-induced constipation in key European countries of Germany, the UK, and the Netherlands, with rights of first refusal for some other European markets.
  • In Dec 2019, 3M has entered into an agreement to sell its drug delivery business to an affiliate of Altaris Capital Partners, LLC for approximately $650 million.

Key Companies to Watch

Pfizer Inc.:

Overview: Pfizer Inc. is an American multinational pharmaceutical corporation that works in biotechnology domain also. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, immunology.

Product Portfolio:

NEXJECT Prefilled Syringe: Nexject is a prefilled all in one syringe that contains multiple levels of technology such as temper-resistant and temper-evident. It is developed for efficient and easy delivery of medicines.

Key Developments: In Jan 2022, Pfizer announced its development and option agreement with Acuitas Therapeutics, company that develops lipid nanoparticle delivery system and m-RNA based therapeutics.

The global drug delivery devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising Prevalence of Chronic Diseases
    • 4.2.2. Increasing Technological Advancements
  • 4.3. Restraints
    • 4.3.1. Quality and Stringent Regulations
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. By COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Injectable Drug Delivery
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2021-2028
    • 7.2.3. Self-Injection Devices
    • 7.2.4. Pen Injectors
      • 7.2.4.1. Autoinjectors
      • 7.2.4.2. Needle-Free Injectors
      • 7.2.4.3. Wearable Injectors
    • 7.2.5. Others
  • 7.3. Nasal Drug Delivery
    • 7.3.1. Mucosal Atomization Devices
    • 7.3.2. Nebulizer
    • 7.3.3. Sinus Implant
    • 7.3.4. Nasal Spray
    • 7.3.5. Nasal Irrigation
    • 7.3.6. Insufflators
    • 7.3.7. Others
  • 7.4. Oral Drug Delivery
    • 7.4.1. Microneedle Capsule
    • 7.4.2. Buccal Tablets
    • 7.4.3. Others
  • 7.5. Topical Drug Delivery
    • 7.5.1. Transdermal Patches
    • 7.5.2. Others
  • 7.6. Implantable Drug Delivery
    • 7.6.1. Active Implantable Drug Delivery
    • 7.6.2. Passive Implantable Drug Delivery
  • 7.7. Pulmonary Drug Delivery
    • 7.7.1. Nebulizers
      • 7.7.1.1. Jet Nebulizers
      • 7.7.1.2. Ultrasonic Nebulizers
      • 7.7.1.3. Soft Mist Nebulizers
    • 7.7.2. Metered-Dose Inhalers
    • 7.7.3. Dry Powder Inhalers
    • 7.7.4. Others
  • 7.8. Ocular Drug Delivery
    • 7.8.1. Drug-Coated Contact Lenses
    • 7.8.2. Ocular Inserts
    • 7.8.3. Others
  • 7.9. Other Drug Delivery Systems
    • 7.9.1. Reconstitution Delivery System
    • 7.9.2. Infusion System
    • 7.9.3. Infusors
    • 7.9.4. Intermates
    • 7.9.5. Needlefree systems
    • 7.9.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2021-2028
  • 8.3. Infectious Diseases
  • 8.4. Respiratory Diseases
  • 8.5. Cardiovascular Diseases
  • 8.6. Central Nervous System Disorders
  • 8.7. Autoimmune Diseases
  • 8.8. Diabetes
  • 8.9. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2021-2028
  • 9.3. Diagnostic Centers
  • 9.4. Ambulatory Surgery Centers
  • 9.5. Home Care Settings
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East & Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Johnson & Johnson
  • 12.3. Novartis AG
  • 12.4. F. Hoffmann-La Roche AG
  • 12.5. Becton, Dickinson and Company
  • 12.6. Sanofi
  • 12.7. Boehringer Ingelheim
  • 12.8. Merck & Co., Inc.
  • 12.9. Boston Scientific Corporation
  • 12.10. Teva Pharmaceuticals Industries Ltd
  • 12.11. AbbVie Inc.

LIST NOT EXHAUSTIVE

13. Global Drug Delivery Devices Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Method of Fixation
  • 13.3. Contact Us